HAGGERTY POLICY SOLUTIONS for AMGEN
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues (Sanders amendments) 340B expansion generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY | — |
Medicare/Medicaid MMM
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.